Vyndaqel and Vyndamax were approved by the FDA in May 2019 for the treatment of patients with transthyretin cardiomyopathy (ATTR-CM). As the only FDA-approved therapies for ATTR-CM, Vyndaqel and Vyndamax are first-in-class launch products with the potential to significantly impact patients and standards of care. As a leader in ATTR CM the Vyndamax team is deeply dedicated to overcoming the challenges faced by patients, along the full patient journey and this role specifically focuses on the unique challenges faced by rare cardiology patients. Rarely has there been an opportunity in a single market to help so many patients with so much at stake and so many challenges to start and stay on therapy. The Vyndamax Senior Manager will work to support advocacy across stakeholders. The position requires strong strategic and analytical skills, exceptional cross-functional collaboration, and detail-oriented execution within a complex and rapidly evolving advocacy landscape. This position is based in NYHQ and reports to the Senior Director, Vyndamax Organized Customer and Access.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
5,001-10,000 employees